-

04:42:57 AM

BNTX Stock News

BNTX - BioNTech SE

06/02/23 6:45 AM

Nasdaq : BNTX

clinical trial

BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO

BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC) Interim data of BNT316/ONC-392 from the ongoing Phase 1/2

RHEA-AI

neutral

05/08/23 6:45 AM

Nasdaq : BNTX

earnings

BioNTech Announces First Quarter 2023 Financial Results and Corporate Update

COVID-19 vaccine franchise focused on vaccine adaptation readiness ahead of the fall season and advancing next generation vaccine candidates and combinations BioNTech and partner OncoC4 plan to start a Phase 3 clinical trial evaluating anti-CTLA-4 antibody BNT316 (ONC-392) as monotherapy in NSCLC

RHEA-AI

neutral

04/24/23 6:45 AM

Nasdaq : BNTX

conferencesearnings

BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023

MAINZ, Germany , April 24, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2023 on Monday, May 8 th, 2023. BioNTech invites investors and the general public to join a conference call and webcast with

RHEA-AI

neutral

04/03/23 6:45 AM

Nasdaq : BNTX

partnership

BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors

BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets expressed in a broad range of human cancers Collaboration will add a new class of precision medicine therapeutics to BioNTech’s clinical-stage

RHEA-AI

positive

03/28/23 6:45 AM

Nasdaq : BNTX

buyback

BioNTech Announces New ADS Repurchase Program

BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that it has entered into a new share repurchase program (the “Program”), pursuant to which the Company may purchase American Depositary Shares, each representing one ordinary

RHEA-AI

neutral

03/27/23 6:45 AM

Nasdaq : BNTX

earnings

BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

Expanded and advanced oncology pipeline to 20 programs in 24 ongoing clinical trials including five ongoing randomized Phase 2 clinical trials; multiple trials with registrational potential expected to be initiated in 2023 and 2024 Announced licensing agreement with OncoC4 to complement the

RHEA-AI

positive

03/20/23 7:45 AM

Nasdaq : BNTX

BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications

BioNTech to receive exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 monoclonal antibody candidate, ONC-392 BioNTech and OncoC4 will co-develop ONC-392 as monotherapy or in combination with anti-PD1 in various solid tumor indications, with a randomized Phase 3

RHEA-AI

very positive

03/13/23 7:45 AM

Nasdaq : BNTX

conferencesearnings

BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023

MAINZ, Germany , March 13, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2022 on Monday, March 27 th, 2023. BioNTech invites investors and the general public to join a conference call and

RHEA-AI

neutral

03/01/23 8:00 AM

Nasdaq : BNTX

BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel

JERUSALEM, Israel, March 1, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) announced that the Company and the Weizmann Institute of Science (“Weizmann Institute”) signed a Memorandum of Understanding (MoU). As part of this MoU, scientists from a variety of disciplines from BioNTech

RHEA-AI

positive

02/02/23 6:45 AM

Nasdaq : BNTX

BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility

Plasmids are an important starting material for the manufacturing of mRNA- and cell-based drugs The new plasmid manufacturing facility aims to increase BioNTech’s autonomy and flexibility in manufacturing an important starting material for its oncology and COVID-19 vaccine pipeline The investment

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next